M Trevisin1, P Neeson, J Savige. 1. Immunology Unit, Division of Laboratory Medicine, Austin Hospital, Heidelberg, Victoria 3084, Australia.
Abstract
BACKGROUND: The demonstration of proteinase 3 specific antineutrophil cytoplasmic antibodies (PR3-ANCA), and the estimation of antibody values are useful in the diagnosis and management of patients with Wegener's granulomatosis (WG). However, external quality assessment programmes suggest that PR3-ANCA binding varies in different assays. AIM: To demonstrate variations in PR3-ANCA binding in different commercial and in house enzyme linked immunosorbent assays (ELISAs). METHOD: Binding of a PR3-ANCA standard and 19 sera from patients with WG was compared in eight commercial and in house assays. Binding was expressed in different units depending on the kit. RESULTS: One commercial assay performed unsatisfactorily. Three commercial kits produced PR3-ANCA binding (70, 102, and 84 U/ml) close to the expected value for the standard (100 U/ml). Serial dilutions of this standard were linear in only one commercial assay and the in house assay. Sera from patients with WG with borderline binding in the in house assay bound in the eight commercial kits at 0-148 kit units; low binding sera ranged from 0 to 273 units; moderately strong sera bound at 7-260 units; and strongly binding sera bound at 13-336 units. In four assays, at least one strongly positive serum bound at levels greater than the provided range. CONCLUSIONS: Levels of antibody binding and units of binding have not been standardised in commercially available PR3-ANCA ELISAs. This may affect the diagnosis and management of patients with WG, in addition to the implementation of international guidelines for treatment.
BACKGROUND: The demonstration of proteinase 3 specific antineutrophil cytoplasmic antibodies (PR3-ANCA), and the estimation of antibody values are useful in the diagnosis and management of patients with Wegener's granulomatosis (WG). However, external quality assessment programmes suggest that PR3-ANCA binding varies in different assays. AIM: To demonstrate variations in PR3-ANCA binding in different commercial and in house enzyme linked immunosorbent assays (ELISAs). METHOD: Binding of a PR3-ANCA standard and 19 sera from patients with WG was compared in eight commercial and in house assays. Binding was expressed in different units depending on the kit. RESULTS: One commercial assay performed unsatisfactorily. Three commercial kits produced PR3-ANCA binding (70, 102, and 84 U/ml) close to the expected value for the standard (100 U/ml). Serial dilutions of this standard were linear in only one commercial assay and the in house assay. Sera from patients with WG with borderline binding in the in house assay bound in the eight commercial kits at 0-148 kit units; low binding sera ranged from 0 to 273 units; moderately strong sera bound at 7-260 units; and strongly binding sera bound at 13-336 units. In four assays, at least one strongly positive serum bound at levels greater than the provided range. CONCLUSIONS: Levels of antibody binding and units of binding have not been standardised in commercially available PR3-ANCA ELISAs. This may affect the diagnosis and management of patients with WG, in addition to the implementation of international guidelines for treatment.
Authors: J W Tervaert; F J van der Woude; A S Fauci; J L Ambrus; J Velosa; W F Keane; S Meijer; M van der Giessen; G K van der Hem; T H The Journal: Arch Intern Med Date: 1989-11
Authors: J Savige; D Gillis; E Benson; D Davies; V Esnault; R J Falk; E C Hagen; D Jayne; J C Jennette; B Paspaliaris; W Pollock; C Pusey; C O Savage; R Silvestrini; F van der Woude; J Wieslander; A Wiik Journal: Am J Clin Pathol Date: 1999-04 Impact factor: 2.493
Authors: E C Hagen; K Andrassy; E Chernok; M R Daha; G Gaskin; W Gross; P Lesavre; J Lüdemann; C D Pusey; N Rasmussen Journal: J Immunol Methods Date: 1993-02-26 Impact factor: 2.303
Authors: F J van der Woude; N Rasmussen; S Lobatto; A Wiik; H Permin; L A van Es; M van der Giessen; G K van der Hem; T H The Journal: Lancet Date: 1985-02-23 Impact factor: 79.321
Authors: R Goldschmeding; C E van der Schoot; D ten Bokkel Huinink; C E Hack; M E van den Ende; C G Kallenberg; A E von dem Borne Journal: J Clin Invest Date: 1989-11 Impact factor: 14.808
Authors: A S Lee; J D Finkielman; T Peikert; A M Hummel; M A Viss; G L Jacob; H A Homburger; U Specks Journal: Clin Exp Immunol Date: 2006-10 Impact factor: 4.330
Authors: Laura M Stinton; Chelsea Bentow; Michael Mahler; Gary L Norman; Bertus Eksteen; Andrew L Mason; Gilaad G Kaplan; Bjorn Lindkvist; Gideon M Hirschfield; Piotr Milkiewicz; Angela Cheung; Harry L A Janssen; Marvin J Fritzler Journal: PLoS One Date: 2014-11-14 Impact factor: 3.240